BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Caliper Life Sciences (CALP) Announces Launch of LabChip(R) Dx for Molecular Diagnostics


1/11/2011 6:21:43 AM

HOPKINTON, Mass., Jan. 11, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced the launch of Caliper's new, innovative LabChip Dx system for use by clinical research laboratories developing molecular diagnostic tests. The LabChip Dx platform is now available in major markets around the world and enables simultaneous analysis of up to ten different analytes in a single sample. The LabChip Dx system is the latest next generation product platform utilizing Caliper's microfluidic technology and intellectual property, and delivers ease of use combined with rapid, accurate, and cost-effective testing. It is also capable of analyzing large numbers of multiplex samples using minimal sample volume and avoids the need to further purify or dilute diagnostic PCR products. The new system includes specific identification, scoring and reporting software. The cost-effective approach of Caliper's robust microfluidics technology has contributed to its high rate of adoption among research laboratories around the world.

"The market has been evolving to run multiple tests simultaneously, and our LabChip Dx product is intended to address this trend," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "This launch is the first step in our strategy to penetrate the molecular diagnostics market. We are currently seeking partners with unique molecular diagnostic content for validation and clearance by regulatory agencies. Long-term, we intend to combine our molecular diagnostics competencies with our recently acquired multiplex tissue imaging technology to enter the emerging field of companion diagnostics."

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results to translate those results into potential cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

The LabChip Dx utilizes Caliper's innovative microfluidics technology to perform reproducible, high-resolution, electrophoretic separations for analyzing multiplex PCR products. The LabChip Dx is labeled "For Research Use Only." It has not been cleared or approved by the U.S. Food and Drug Administration.

The statements in this press release regarding future events, including statements regarding Caliper's intent to combine its molecular diagnostics competencies with its recently acquired multiplex tissue imaging technology to enter the emerging field of companion diagnostics, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that Caliper may not be able to convince potential partners who have unique molecular diagnostic content of the superior performance of its LabChip Dx platform, or applicable regulatory agencies may not approve the LabChip Dx platform for diagnostic applications. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2009. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.

SOURCE Caliper Life Sciences, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES